nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—blood plasma—hepatitis B	0.0142	0.276	CbGeAlD
Everolimus—FKBP1A—blood plasma—hepatitis B	0.0128	0.248	CbGeAlD
Everolimus—MTOR—blood—hepatitis B	0.00522	0.101	CbGeAlD
Everolimus—FKBP1A—blood—hepatitis B	0.00469	0.0909	CbGeAlD
Everolimus—CYP3A4—blood plasma—hepatitis B	0.00419	0.0811	CbGeAlD
Everolimus—MTOR—liver—hepatitis B	0.00408	0.079	CbGeAlD
Everolimus—FKBP1A—liver—hepatitis B	0.00367	0.0711	CbGeAlD
Everolimus—Musculoskeletal pain—Telbivudine—hepatitis B	0.0035	0.00491	CcSEcCtD
Everolimus—Hepatic failure—Entecavir—hepatitis B	0.0034	0.00477	CcSEcCtD
Everolimus—Hypertriglyceridaemia—Lamivudine—hepatitis B	0.00339	0.00476	CcSEcCtD
Everolimus—Hepatic failure—Adefovir Dipivoxil—hepatitis B	0.00331	0.00465	CcSEcCtD
Everolimus—Renal impairment—Adefovir Dipivoxil—hepatitis B	0.00313	0.00439	CcSEcCtD
Everolimus—Folliculitis—Lamivudine—hepatitis B	0.0031	0.00435	CcSEcCtD
Everolimus—Respiratory tract infection—Lamivudine—hepatitis B	0.0031	0.00435	CcSEcCtD
Everolimus—Sepsis—Telbivudine—hepatitis B	0.003	0.00421	CcSEcCtD
Everolimus—Blood triglycerides increased—Lamivudine—hepatitis B	0.00297	0.00417	CcSEcCtD
Everolimus—Blood creatinine increased—Entecavir—hepatitis B	0.00286	0.00402	CcSEcCtD
Everolimus—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00279	0.00392	CcSEcCtD
Everolimus—Abdominal pain upper—Entecavir—hepatitis B	0.00279	0.00391	CcSEcCtD
Everolimus—Liver function test abnormal—Adefovir Dipivoxil—hepatitis B	0.00275	0.00386	CcSEcCtD
Everolimus—Renal impairment—Telbivudine—hepatitis B	0.00264	0.0037	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.00263	0.00369	CcSEcCtD
Everolimus—Pancreatitis—Entecavir—hepatitis B	0.00259	0.00363	CcSEcCtD
Everolimus—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.00252	0.00354	CcSEcCtD
Everolimus—Pain in extremity—Telbivudine—hepatitis B	0.00251	0.00352	CcSEcCtD
Everolimus—Migraine—Telbivudine—hepatitis B	0.00247	0.00347	CcSEcCtD
Everolimus—Neutropenia—Entecavir—hepatitis B	0.00247	0.00346	CcSEcCtD
Everolimus—Upper respiratory tract infection—Entecavir—hepatitis B	0.00245	0.00344	CcSEcCtD
Everolimus—Rhinorrhoea—Lamivudine—hepatitis B	0.0024	0.00337	CcSEcCtD
Everolimus—Hyperglycaemia—Entecavir—hepatitis B	0.00238	0.00334	CcSEcCtD
Everolimus—Blood disorder—Lamivudine—hepatitis B	0.00233	0.00327	CcSEcCtD
Everolimus—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00233	0.00327	CcSEcCtD
Everolimus—Acne—Lamivudine—hepatitis B	0.00231	0.00325	CcSEcCtD
Everolimus—Renal failure—Entecavir—hepatitis B	0.00231	0.00325	CcSEcCtD
Everolimus—Abdominal pain upper—Telbivudine—hepatitis B	0.00229	0.00322	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00226	0.00317	CcSEcCtD
Everolimus—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00226	0.00317	CcSEcCtD
Everolimus—Haematuria—Entecavir—hepatitis B	0.00224	0.00315	CcSEcCtD
Everolimus—Nasopharyngitis—Telbivudine—hepatitis B	0.00224	0.00315	CcSEcCtD
Everolimus—Jaundice—Adefovir Dipivoxil—hepatitis B	0.00224	0.00314	CcSEcCtD
Everolimus—Hepatobiliary disease—Entecavir—hepatitis B	0.00223	0.00312	CcSEcCtD
Everolimus—Gastritis—Telbivudine—hepatitis B	0.00222	0.00312	CcSEcCtD
Everolimus—Muscular weakness—Telbivudine—hepatitis B	0.00221	0.00311	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00221	0.00311	CcSEcCtD
Everolimus—Rhabdomyolysis—Lamivudine—hepatitis B	0.0022	0.00309	CcSEcCtD
Everolimus—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00219	0.00307	CcSEcCtD
Everolimus—Abdominal distension—Telbivudine—hepatitis B	0.00218	0.00306	CcSEcCtD
Everolimus—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00217	0.00305	CcSEcCtD
Everolimus—Influenza—Telbivudine—hepatitis B	0.00217	0.00304	CcSEcCtD
Everolimus—Viral infection—Lamivudine—hepatitis B	0.00216	0.00303	CcSEcCtD
Everolimus—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.00215	0.00302	CcSEcCtD
Everolimus—Oropharyngeal pain—Lamivudine—hepatitis B	0.00214	0.00301	CcSEcCtD
Everolimus—Hepatitis—Entecavir—hepatitis B	0.00211	0.00296	CcSEcCtD
Everolimus—Oedema peripheral—Entecavir—hepatitis B	0.00208	0.00292	CcSEcCtD
Everolimus—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00206	0.00289	CcSEcCtD
Everolimus—Hypercholesterolaemia—Lamivudine—hepatitis B	0.00206	0.00289	CcSEcCtD
Everolimus—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.00205	0.00287	CcSEcCtD
Everolimus—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00204	0.00286	CcSEcCtD
Everolimus—Neutropenia—Telbivudine—hepatitis B	0.00203	0.00285	CcSEcCtD
Everolimus—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00203	0.00284	CcSEcCtD
Everolimus—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00202	0.00284	CcSEcCtD
Everolimus—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00201	0.00283	CcSEcCtD
Everolimus—Inflammation—Lamivudine—hepatitis B	0.00201	0.00282	CcSEcCtD
Everolimus—Musculoskeletal pain—Lamivudine—hepatitis B	0.00197	0.00277	CcSEcCtD
Everolimus—Immune system disorder—Entecavir—hepatitis B	0.00191	0.00268	CcSEcCtD
Everolimus—Renal failure—Telbivudine—hepatitis B	0.0019	0.00267	CcSEcCtD
Everolimus—Wheezing—Lamivudine—hepatitis B	0.00189	0.00265	CcSEcCtD
Everolimus—Alopecia—Entecavir—hepatitis B	0.00187	0.00262	CcSEcCtD
Everolimus—Mental disorder—Entecavir—hepatitis B	0.00185	0.0026	CcSEcCtD
Everolimus—Malnutrition—Entecavir—hepatitis B	0.00184	0.00258	CcSEcCtD
Everolimus—Hepatobiliary disease—Telbivudine—hepatitis B	0.00183	0.00257	CcSEcCtD
Everolimus—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00179	0.00252	CcSEcCtD
Everolimus—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00177	0.00248	CcSEcCtD
Everolimus—Urine output increased—Lamivudine—hepatitis B	0.00176	0.00247	CcSEcCtD
Everolimus—Mouth ulceration—Lamivudine—hepatitis B	0.00176	0.00247	CcSEcCtD
Everolimus—Back pain—Adefovir Dipivoxil—hepatitis B	0.00174	0.00244	CcSEcCtD
Everolimus—Hepatitis—Telbivudine—hepatitis B	0.00174	0.00244	CcSEcCtD
Everolimus—Hypoaesthesia—Telbivudine—hepatitis B	0.00173	0.00242	CcSEcCtD
Everolimus—Pharyngitis—Telbivudine—hepatitis B	0.00172	0.00242	CcSEcCtD
Everolimus—Connective tissue disorder—Telbivudine—hepatitis B	0.00171	0.00239	CcSEcCtD
Everolimus—Sepsis—Lamivudine—hepatitis B	0.00169	0.00237	CcSEcCtD
Everolimus—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00166	0.00233	CcSEcCtD
Everolimus—Lymphadenopathy—Lamivudine—hepatitis B	0.00166	0.00233	CcSEcCtD
Everolimus—Leukopenia—Entecavir—hepatitis B	0.00165	0.00231	CcSEcCtD
Everolimus—Polyuria—Lamivudine—hepatitis B	0.00161	0.00226	CcSEcCtD
Everolimus—Gastroenteritis—Lamivudine—hepatitis B	0.00159	0.00224	CcSEcCtD
Everolimus—Cough—Adefovir Dipivoxil—hepatitis B	0.00157	0.0022	CcSEcCtD
Everolimus—Mediastinal disorder—Telbivudine—hepatitis B	0.00156	0.0022	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00155	0.00218	CcSEcCtD
Everolimus—CYP3A4—blood—hepatitis B	0.00153	0.0297	CbGeAlD
Everolimus—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00153	0.00214	CcSEcCtD
Everolimus—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00153	0.00214	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00152	0.00213	CcSEcCtD
Everolimus—Malnutrition—Telbivudine—hepatitis B	0.00151	0.00212	CcSEcCtD
Everolimus—Infection—Entecavir—hepatitis B	0.00149	0.00209	CcSEcCtD
Everolimus—Renal impairment—Lamivudine—hepatitis B	0.00149	0.00208	CcSEcCtD
Everolimus—Dysgeusia—Telbivudine—hepatitis B	0.00148	0.00208	CcSEcCtD
Everolimus—Nervous system disorder—Entecavir—hepatitis B	0.00147	0.00207	CcSEcCtD
Everolimus—Back pain—Telbivudine—hepatitis B	0.00146	0.00205	CcSEcCtD
Everolimus—Skin disorder—Entecavir—hepatitis B	0.00146	0.00205	CcSEcCtD
Everolimus—Muscle spasms—Telbivudine—hepatitis B	0.00145	0.00204	CcSEcCtD
Everolimus—Hypoglycaemia—Lamivudine—hepatitis B	0.00145	0.00203	CcSEcCtD
Everolimus—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00144	0.00202	CcSEcCtD
Everolimus—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00143	0.00201	CcSEcCtD
Everolimus—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00142	0.002	CcSEcCtD
Everolimus—Ill-defined disorder—Telbivudine—hepatitis B	0.0014	0.00197	CcSEcCtD
Everolimus—Anorexia—Adefovir Dipivoxil—hepatitis B	0.0014	0.00196	CcSEcCtD
Everolimus—Migraine—Lamivudine—hepatitis B	0.00139	0.00195	CcSEcCtD
Everolimus—Malaise—Telbivudine—hepatitis B	0.00136	0.00191	CcSEcCtD
Everolimus—Insomnia—Entecavir—hepatitis B	0.00136	0.00191	CcSEcCtD
Everolimus—Somnolence—Entecavir—hepatitis B	0.00133	0.00187	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00133	0.00187	CcSEcCtD
Everolimus—Dyspepsia—Entecavir—hepatitis B	0.00132	0.00185	CcSEcCtD
Everolimus—Cough—Telbivudine—hepatitis B	0.00132	0.00185	CcSEcCtD
Everolimus—Dehydration—Lamivudine—hepatitis B	0.00131	0.00185	CcSEcCtD
Everolimus—Liver function test abnormal—Lamivudine—hepatitis B	0.00131	0.00183	CcSEcCtD
Everolimus—Gastrointestinal disorder—Entecavir—hepatitis B	0.0013	0.00182	CcSEcCtD
Everolimus—Fatigue—Entecavir—hepatitis B	0.00129	0.00182	CcSEcCtD
Everolimus—Abdominal pain upper—Lamivudine—hepatitis B	0.00129	0.00181	CcSEcCtD
Everolimus—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00129	0.00181	CcSEcCtD
Everolimus—Arthralgia—Telbivudine—hepatitis B	0.00129	0.00181	CcSEcCtD
Everolimus—Chest pain—Telbivudine—hepatitis B	0.00129	0.00181	CcSEcCtD
Everolimus—Myalgia—Telbivudine—hepatitis B	0.00129	0.00181	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00128	0.00179	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00127	0.00179	CcSEcCtD
Everolimus—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00127	0.00179	CcSEcCtD
Everolimus—Discomfort—Telbivudine—hepatitis B	0.00127	0.00178	CcSEcCtD
Everolimus—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00126	0.00177	CcSEcCtD
Everolimus—Nasopharyngitis—Lamivudine—hepatitis B	0.00126	0.00177	CcSEcCtD
Everolimus—Muscular weakness—Lamivudine—hepatitis B	0.00125	0.00175	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00125	0.00175	CcSEcCtD
Everolimus—Abdominal distension—Lamivudine—hepatitis B	0.00123	0.00173	CcSEcCtD
Everolimus—Gastrointestinal pain—Entecavir—hepatitis B	0.00123	0.00172	CcSEcCtD
Everolimus—Influenza—Lamivudine—hepatitis B	0.00122	0.00171	CcSEcCtD
Everolimus—Dysphagia—Lamivudine—hepatitis B	0.00122	0.00171	CcSEcCtD
Everolimus—Nervous system disorder—Telbivudine—hepatitis B	0.00121	0.0017	CcSEcCtD
Everolimus—Thrombocytopenia—Telbivudine—hepatitis B	0.00121	0.00169	CcSEcCtD
Everolimus—CYP3A4—liver—hepatitis B	0.0012	0.0232	CbGeAlD
Everolimus—Pancreatitis—Lamivudine—hepatitis B	0.0012	0.00168	CcSEcCtD
Everolimus—Skin disorder—Telbivudine—hepatitis B	0.0012	0.00168	CcSEcCtD
Everolimus—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.0012	0.00168	CcSEcCtD
Everolimus—Abdominal pain—Entecavir—hepatitis B	0.00119	0.00167	CcSEcCtD
Everolimus—Body temperature increased—Entecavir—hepatitis B	0.00119	0.00167	CcSEcCtD
Everolimus—Bronchitis—Lamivudine—hepatitis B	0.00117	0.00165	CcSEcCtD
Everolimus—Pancytopenia—Lamivudine—hepatitis B	0.00116	0.00163	CcSEcCtD
Everolimus—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00116	0.00162	CcSEcCtD
Everolimus—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00116	0.00162	CcSEcCtD
Everolimus—Neutropenia—Lamivudine—hepatitis B	0.00114	0.0016	CcSEcCtD
Everolimus—Dysuria—Lamivudine—hepatitis B	0.00114	0.0016	CcSEcCtD
Everolimus—Pollakiuria—Lamivudine—hepatitis B	0.00113	0.00158	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.00112	0.00158	CcSEcCtD
Everolimus—Insomnia—Telbivudine—hepatitis B	0.00111	0.00157	CcSEcCtD
Everolimus—Paraesthesia—Telbivudine—hepatitis B	0.00111	0.00155	CcSEcCtD
Everolimus—Hyperglycaemia—Lamivudine—hepatitis B	0.0011	0.00155	CcSEcCtD
Everolimus—Dyspepsia—Telbivudine—hepatitis B	0.00109	0.00152	CcSEcCtD
Everolimus—Asthenia—Entecavir—hepatitis B	0.00108	0.00151	CcSEcCtD
Everolimus—Renal failure—Lamivudine—hepatitis B	0.00107	0.0015	CcSEcCtD
Everolimus—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00106	0.00149	CcSEcCtD
Everolimus—Fatigue—Telbivudine—hepatitis B	0.00106	0.00149	CcSEcCtD
Everolimus—Jaundice—Lamivudine—hepatitis B	0.00106	0.00149	CcSEcCtD
Everolimus—Stomatitis—Lamivudine—hepatitis B	0.00106	0.00149	CcSEcCtD
Everolimus—Pain—Telbivudine—hepatitis B	0.00105	0.00148	CcSEcCtD
Everolimus—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00105	0.00147	CcSEcCtD
Everolimus—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00104	0.00145	CcSEcCtD
Everolimus—Hepatobiliary disease—Lamivudine—hepatitis B	0.00103	0.00145	CcSEcCtD
Everolimus—Epistaxis—Lamivudine—hepatitis B	0.00103	0.00144	CcSEcCtD
Everolimus—Diarrhoea—Entecavir—hepatitis B	0.00103	0.00144	CcSEcCtD
Everolimus—Sinusitis—Lamivudine—hepatitis B	0.00102	0.00143	CcSEcCtD
Everolimus—Feeling abnormal—Telbivudine—hepatitis B	0.00102	0.00143	CcSEcCtD
Everolimus—Gastrointestinal pain—Telbivudine—hepatitis B	0.00101	0.00142	CcSEcCtD
Everolimus—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.001	0.00141	CcSEcCtD
Everolimus—Dizziness—Entecavir—hepatitis B	0.000992	0.00139	CcSEcCtD
Everolimus—Rhinitis—Lamivudine—hepatitis B	0.00098	0.00138	CcSEcCtD
Everolimus—Hepatitis—Lamivudine—hepatitis B	0.000978	0.00137	CcSEcCtD
Everolimus—Abdominal pain—Telbivudine—hepatitis B	0.000975	0.00137	CcSEcCtD
Everolimus—Body temperature increased—Telbivudine—hepatitis B	0.000975	0.00137	CcSEcCtD
Everolimus—Hypoaesthesia—Lamivudine—hepatitis B	0.000973	0.00137	CcSEcCtD
Everolimus—Pharyngitis—Lamivudine—hepatitis B	0.000971	0.00136	CcSEcCtD
Everolimus—Connective tissue disorder—Lamivudine—hepatitis B	0.000961	0.00135	CcSEcCtD
Everolimus—Vomiting—Entecavir—hepatitis B	0.000954	0.00134	CcSEcCtD
Everolimus—Rash—Entecavir—hepatitis B	0.000946	0.00133	CcSEcCtD
Everolimus—Dermatitis—Entecavir—hepatitis B	0.000945	0.00133	CcSEcCtD
Everolimus—Headache—Entecavir—hepatitis B	0.00094	0.00132	CcSEcCtD
Everolimus—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000931	0.00131	CcSEcCtD
Everolimus—Rash—Adefovir Dipivoxil—hepatitis B	0.000923	0.0013	CcSEcCtD
Everolimus—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000922	0.00129	CcSEcCtD
Everolimus—Headache—Adefovir Dipivoxil—hepatitis B	0.000917	0.00129	CcSEcCtD
Everolimus—Nausea—Entecavir—hepatitis B	0.000891	0.00125	CcSEcCtD
Everolimus—Asthenia—Telbivudine—hepatitis B	0.000884	0.00124	CcSEcCtD
Everolimus—Immune system disorder—Lamivudine—hepatitis B	0.000883	0.00124	CcSEcCtD
Everolimus—Mediastinal disorder—Lamivudine—hepatitis B	0.000881	0.00124	CcSEcCtD
Everolimus—Chills—Lamivudine—hepatitis B	0.000877	0.00123	CcSEcCtD
Everolimus—Pruritus—Telbivudine—hepatitis B	0.000872	0.00122	CcSEcCtD
Everolimus—Nausea—Adefovir Dipivoxil—hepatitis B	0.00087	0.00122	CcSEcCtD
Everolimus—Alopecia—Lamivudine—hepatitis B	0.000864	0.00121	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—NFKB1—hepatitis B	0.000861	0.00366	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL2—hepatitis B	0.000858	0.00364	CbGpPWpGaD
Everolimus—Malnutrition—Lamivudine—hepatitis B	0.000851	0.00119	CcSEcCtD
Everolimus—Erythema—Lamivudine—hepatitis B	0.000851	0.00119	CcSEcCtD
Everolimus—Diarrhoea—Telbivudine—hepatitis B	0.000843	0.00118	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—hepatitis B	0.000843	0.00358	CbGpPWpGaD
Everolimus—Flatulence—Lamivudine—hepatitis B	0.000839	0.00118	CcSEcCtD
Everolimus—Dysgeusia—Lamivudine—hepatitis B	0.000834	0.00117	CcSEcCtD
Everolimus—Back pain—Lamivudine—hepatitis B	0.000823	0.00116	CcSEcCtD
Everolimus—Muscle spasms—Lamivudine—hepatitis B	0.000818	0.00115	CcSEcCtD
Everolimus—Dizziness—Telbivudine—hepatitis B	0.000815	0.00114	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—NFKB1—hepatitis B	0.000803	0.00341	CbGpPWpGaD
Everolimus—Tremor—Lamivudine—hepatitis B	0.000798	0.00112	CcSEcCtD
Everolimus—Ill-defined disorder—Lamivudine—hepatitis B	0.00079	0.00111	CcSEcCtD
Everolimus—Anaemia—Lamivudine—hepatitis B	0.000787	0.0011	CcSEcCtD
Everolimus—Vomiting—Telbivudine—hepatitis B	0.000784	0.0011	CcSEcCtD
Everolimus—Angioedema—Lamivudine—hepatitis B	0.000778	0.00109	CcSEcCtD
Everolimus—Rash—Telbivudine—hepatitis B	0.000777	0.00109	CcSEcCtD
Everolimus—Dermatitis—Telbivudine—hepatitis B	0.000777	0.00109	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—IL2—hepatitis B	0.000776	0.00329	CbGpPWpGaD
Everolimus—Headache—Telbivudine—hepatitis B	0.000772	0.00108	CcSEcCtD
Everolimus—Malaise—Lamivudine—hepatitis B	0.000768	0.00108	CcSEcCtD
Everolimus—Syncope—Lamivudine—hepatitis B	0.000763	0.00107	CcSEcCtD
Everolimus—Leukopenia—Lamivudine—hepatitis B	0.000762	0.00107	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HLA-DPA1—hepatitis B	0.000761	0.00323	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SAG—hepatitis B	0.000758	0.00322	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOBEC3G—hepatitis B	0.000758	0.00322	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—NFKB1—hepatitis B	0.000753	0.0032	CbGpPWpGaD
Everolimus—Loss of consciousness—Lamivudine—hepatitis B	0.000748	0.00105	CcSEcCtD
Everolimus—Cough—Lamivudine—hepatitis B	0.000743	0.00104	CcSEcCtD
Everolimus—Convulsion—Lamivudine—hepatitis B	0.000738	0.00104	CcSEcCtD
Everolimus—Nausea—Telbivudine—hepatitis B	0.000732	0.00103	CcSEcCtD
Everolimus—MTOR—CDC42 signaling events—CTNNB1—hepatitis B	0.000732	0.00311	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—NFKB1—hepatitis B	0.000727	0.00309	CbGpPWpGaD
Everolimus—Myalgia—Lamivudine—hepatitis B	0.000725	0.00102	CcSEcCtD
Everolimus—Chest pain—Lamivudine—hepatitis B	0.000725	0.00102	CcSEcCtD
Everolimus—Arthralgia—Lamivudine—hepatitis B	0.000725	0.00102	CcSEcCtD
Everolimus—MTOR—AMPK Signaling—CDKN1A—hepatitis B	0.000723	0.00307	CbGpPWpGaD
Everolimus—Anxiety—Lamivudine—hepatitis B	0.000722	0.00101	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—UBE2L3—hepatitis B	0.000722	0.00306	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD274—hepatitis B	0.000722	0.00306	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00072	0.00101	CcSEcCtD
Everolimus—MTOR—LKB1 signaling events—TP53—hepatitis B	0.000719	0.00305	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—hepatitis B	0.000717	0.00305	CbGpPWpGaD
Everolimus—Discomfort—Lamivudine—hepatitis B	0.000716	0.00101	CcSEcCtD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—hepatitis B	0.000712	0.00302	CbGpPWpGaD
Everolimus—Dry mouth—Lamivudine—hepatitis B	0.000709	0.000995	CcSEcCtD
Everolimus—Oedema—Lamivudine—hepatitis B	0.000695	0.000975	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TGFB1—hepatitis B	0.000692	0.00294	CbGpPWpGaD
Everolimus—Infection—Lamivudine—hepatitis B	0.00069	0.000969	CcSEcCtD
Everolimus—Shock—Lamivudine—hepatitis B	0.000684	0.000959	CcSEcCtD
Everolimus—Nervous system disorder—Lamivudine—hepatitis B	0.000681	0.000956	CcSEcCtD
Everolimus—Thrombocytopenia—Lamivudine—hepatitis B	0.00068	0.000955	CcSEcCtD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.000676	0.00287	CbGpPWpGaD
Everolimus—Skin disorder—Lamivudine—hepatitis B	0.000675	0.000947	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—NFKB1—hepatitis B	0.000672	0.00285	CbGpPWpGaD
Everolimus—Hyperhidrosis—Lamivudine—hepatitis B	0.000672	0.000943	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—hepatitis B	0.00067	0.00284	CbGpPWpGaD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.000667	0.00283	CbGpPWpGaD
Everolimus—Anorexia—Lamivudine—hepatitis B	0.000662	0.00093	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PDCD1—hepatitis B	0.00066	0.0028	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—hepatitis B	0.000658	0.00279	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IFNB1—hepatitis B	0.00065	0.00276	CbGpPWpGaD
Everolimus—Hypotension—Lamivudine—hepatitis B	0.000649	0.000911	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—hepatitis B	0.000647	0.00275	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000633	0.000889	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—hepatitis B	0.000633	0.00269	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—hepatitis B	0.000632	0.00269	CbGpPWpGaD
Everolimus—Insomnia—Lamivudine—hepatitis B	0.000628	0.000882	CcSEcCtD
Everolimus—Paraesthesia—Lamivudine—hepatitis B	0.000624	0.000876	CcSEcCtD
Everolimus—Dyspnoea—Lamivudine—hepatitis B	0.000619	0.000869	CcSEcCtD
Everolimus—Somnolence—Lamivudine—hepatitis B	0.000618	0.000867	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—hepatitis B	0.000617	0.00262	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—hepatitis B	0.000614	0.00261	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—hepatitis B	0.000613	0.0026	CbGpPWpGaD
Everolimus—Dyspepsia—Lamivudine—hepatitis B	0.000612	0.000858	CcSEcCtD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—CDKN1A—hepatitis B	0.000606	0.00257	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—TGFB1—hepatitis B	0.000605	0.00257	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—PTEN—hepatitis B	0.000605	0.00257	CbGpPWpGaD
Everolimus—Decreased appetite—Lamivudine—hepatitis B	0.000604	0.000848	CcSEcCtD
Everolimus—Gastrointestinal disorder—Lamivudine—hepatitis B	0.0006	0.000842	CcSEcCtD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—hepatitis B	0.000599	0.00254	CbGpPWpGaD
Everolimus—Fatigue—Lamivudine—hepatitis B	0.000599	0.000841	CcSEcCtD
Everolimus—Pain—Lamivudine—hepatitis B	0.000594	0.000834	CcSEcCtD
Everolimus—Constipation—Lamivudine—hepatitis B	0.000594	0.000834	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	0.000583	0.00248	CbGpPWpGaD
Everolimus—Feeling abnormal—Lamivudine—hepatitis B	0.000573	0.000804	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—hepatitis B	0.00057	0.00242	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	0.000569	0.00242	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	0.000568	0.00241	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Lamivudine—hepatitis B	0.000568	0.000797	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	0.000565	0.0024	CbGpPWpGaD
Everolimus—Abdominal pain—Lamivudine—hepatitis B	0.000549	0.000771	CcSEcCtD
Everolimus—Body temperature increased—Lamivudine—hepatitis B	0.000549	0.000771	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.000548	0.00233	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—CDKN1A—hepatitis B	0.000546	0.00232	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—PTEN—hepatitis B	0.000545	0.00231	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—CDKN1A—hepatitis B	0.000533	0.00226	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—PTEN—hepatitis B	0.000532	0.00226	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RIT2—hepatitis B	0.000531	0.00225	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SAG—hepatitis B	0.000531	0.00225	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—CDKN1A—hepatitis B	0.000529	0.00225	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNAR2—hepatitis B	0.000528	0.00224	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—PTEN—hepatitis B	0.000528	0.00224	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—hepatitis B	0.000522	0.00222	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—CTNNB1—hepatitis B	0.000521	0.00221	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN1A—hepatitis B	0.000517	0.00219	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—CDKN1A—hepatitis B	0.000517	0.00219	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—hepatitis B	0.000517	0.00219	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—PTEN—hepatitis B	0.000516	0.00219	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—PTEN—hepatitis B	0.000516	0.00219	CbGpPWpGaD
Everolimus—Hypersensitivity—Lamivudine—hepatitis B	0.000512	0.000719	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—hepatitis B	0.000511	0.00217	CbGpPWpGaD
Everolimus—Asthenia—Lamivudine—hepatitis B	0.000498	0.0007	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—AKR1B1—hepatitis B	0.000494	0.0021	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—hepatitis B	0.000492	0.00209	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—CTNNB1—hepatitis B	0.000492	0.00209	CbGpPWpGaD
Everolimus—Pruritus—Lamivudine—hepatitis B	0.000492	0.00069	CcSEcCtD
Everolimus—Tacrolimus—ALB—hepatitis B	0.00048	1	CrCbGaD
Everolimus—CYP3A4—Biological oxidations—GGT2—hepatitis B	0.00048	0.00204	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—hepatitis B	0.000477	0.00203	CbGpPWpGaD
Everolimus—Diarrhoea—Lamivudine—hepatitis B	0.000475	0.000667	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	0.000471	0.002	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DPA1—hepatitis B	0.000462	0.00196	CbGpPWpGaD
Everolimus—Dizziness—Lamivudine—hepatitis B	0.000459	0.000645	CcSEcCtD
Everolimus—Vomiting—Lamivudine—hepatitis B	0.000442	0.00062	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	0.00044	0.00187	CbGpPWpGaD
Everolimus—Rash—Lamivudine—hepatitis B	0.000438	0.000615	CcSEcCtD
Everolimus—MTOR—Immune System—CD274—hepatitis B	0.000438	0.00186	CbGpPWpGaD
Everolimus—MTOR—Immune System—UBE2L3—hepatitis B	0.000438	0.00186	CbGpPWpGaD
Everolimus—Dermatitis—Lamivudine—hepatitis B	0.000438	0.000614	CcSEcCtD
Everolimus—Headache—Lamivudine—hepatitis B	0.000435	0.000611	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—hepatitis B	0.000428	0.00182	CbGpPWpGaD
Everolimus—MTOR—Disease—APOBEC3G—hepatitis B	0.000426	0.00181	CbGpPWpGaD
Everolimus—MTOR—Disease—SAG—hepatitis B	0.000426	0.00181	CbGpPWpGaD
Everolimus—Nausea—Lamivudine—hepatitis B	0.000413	0.000579	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—CTNNB1—hepatitis B	0.000411	0.00175	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—CDKN1A—hepatitis B	0.000408	0.00173	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PTEN—hepatitis B	0.000407	0.00173	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDCD1—hepatitis B	0.0004	0.0017	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NFKB1—hepatitis B	0.000399	0.00169	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—hepatitis B	0.000396	0.00168	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—CDKN1A—hepatitis B	0.000391	0.00166	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PTEN—hepatitis B	0.00039	0.00166	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	0.000388	0.00165	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—hepatitis B	0.000386	0.00164	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—CDKN1A—hepatitis B	0.000384	0.00163	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—NFKB1—hepatitis B	0.000384	0.00163	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—PTEN—hepatitis B	0.000384	0.00163	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—hepatitis B	0.000381	0.00162	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNGR1—hepatitis B	0.000372	0.00158	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—hepatitis B	0.000371	0.00158	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HSPA5—hepatitis B	0.00037	0.00157	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PTEN—hepatitis B	0.000368	0.00156	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—hepatitis B	0.000368	0.00156	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—CDKN1A—hepatitis B	0.000367	0.00156	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PTEN—hepatitis B	0.000366	0.00156	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—CDKN1A—hepatitis B	0.000365	0.00155	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PTEN—hepatitis B	0.000365	0.00155	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—hepatitis B	0.000365	0.00155	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—CDKN1A—hepatitis B	0.000364	0.00154	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PTEN—hepatitis B	0.000363	0.00154	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—CDKN1A—hepatitis B	0.000362	0.00154	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—PTEN—hepatitis B	0.000361	0.00153	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GOT2—hepatitis B	0.00036	0.00153	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—hepatitis B	0.000358	0.00152	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—hepatitis B	0.000358	0.00152	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1A—hepatitis B	0.000357	0.00151	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—hepatitis B	0.000356	0.00151	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—hepatitis B	0.000354	0.0015	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—hepatitis B	0.000352	0.00149	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR2—hepatitis B	0.00035	0.00149	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DPB1—hepatitis B	0.00035	0.00148	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNB1—hepatitis B	0.000348	0.00148	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CDKN1A—hepatitis B	0.00034	0.00145	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1A—hepatitis B	0.00034	0.00145	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CDKN1A—hepatitis B	0.00034	0.00145	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PTEN—hepatitis B	0.00034	0.00144	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—hepatitis B	0.00034	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PTEN—hepatitis B	0.00034	0.00144	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNA1—hepatitis B	0.000339	0.00144	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKB1—hepatitis B	0.000338	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—CDKN1A—hepatitis B	0.000337	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PTEN—hepatitis B	0.000337	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—hepatitis B	0.000334	0.00142	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PTEN—hepatitis B	0.000334	0.00142	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1A—hepatitis B	0.000333	0.00141	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PTEN—hepatitis B	0.000332	0.00141	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—hepatitis B	0.000322	0.00137	CbGpPWpGaD
Everolimus—MTOR—Immune System—MX1—hepatitis B	0.00032	0.00136	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—hepatitis B	0.000317	0.00135	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD14—hepatitis B	0.000316	0.00134	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNA2—hepatitis B	0.000316	0.00134	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CDKN1A—hepatitis B	0.000315	0.00134	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PTEN—hepatitis B	0.000314	0.00133	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NFKB1—hepatitis B	0.000313	0.00133	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GOT1—hepatitis B	0.000311	0.00132	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—hepatitis B	0.000302	0.00128	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—hepatitis B	0.000301	0.00128	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—hepatitis B	0.000301	0.00128	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—hepatitis B	0.0003	0.00127	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SAG—hepatitis B	0.000299	0.00127	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RIT2—hepatitis B	0.000299	0.00127	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—hepatitis B	0.000297	0.00126	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP2A6—hepatitis B	0.000291	0.00124	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—hepatitis B	0.000263	0.00112	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—hepatitis B	0.000258	0.00109	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—hepatitis B	0.000255	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—hepatitis B	0.000254	0.00108	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN1A—hepatitis B	0.000247	0.00105	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—NFKB1—hepatitis B	0.000245	0.00104	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—hepatitis B	0.000243	0.00103	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—hepatitis B	0.00024	0.00102	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCR5—hepatitis B	0.000232	0.000986	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CDKN1A—hepatitis B	0.000232	0.000985	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTEN—hepatitis B	0.000231	0.000982	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NFKB1—hepatitis B	0.00023	0.000978	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—hepatitis B	0.000229	0.000972	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—hepatitis B	0.000228	0.000967	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-A—hepatitis B	0.000227	0.000965	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GGT1—hepatitis B	0.000227	0.000964	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—hepatitis B	0.000227	0.000962	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HLA-A—hepatitis B	0.000226	0.00096	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—hepatitis B	0.000225	0.000958	CbGpPWpGaD
Everolimus—MTOR—Immune System—HSPA5—hepatitis B	0.000224	0.000953	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—hepatitis B	0.000216	0.000919	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—hepatitis B	0.000212	0.000901	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—hepatitis B	0.000212	0.000901	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—hepatitis B	0.000212	0.000901	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DPB1—hepatitis B	0.000212	0.0009	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—hepatitis B	0.00021	0.000893	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL10—hepatitis B	0.00021	0.00089	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—hepatitis B	0.000208	0.000885	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DRB1—hepatitis B	0.000208	0.000881	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—hepatitis B	0.000207	0.000881	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR2—hepatitis B	0.000204	0.000866	CbGpPWpGaD
Everolimus—MTOR—Disease—GOT2—hepatitis B	0.000203	0.00086	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNB1—hepatitis B	0.000202	0.00086	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA1—hepatitis B	0.000198	0.000839	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—hepatitis B	0.000197	0.000835	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—hepatitis B	0.000188	0.000798	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD14—hepatitis B	0.000184	0.000781	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA2—hepatitis B	0.000184	0.000781	CbGpPWpGaD
Everolimus—MTOR—Disease—GOT1—hepatitis B	0.000175	0.000742	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—hepatitis B	0.000168	0.000715	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—hepatitis B	0.000163	0.00069	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—hepatitis B	0.000157	0.000666	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—hepatitis B	0.000156	0.000664	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—hepatitis B	0.000155	0.000656	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—hepatitis B	0.000154	0.000654	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—hepatitis B	0.000152	0.000647	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—hepatitis B	0.000146	0.000622	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—hepatitis B	0.000146	0.000619	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—hepatitis B	0.000145	0.000614	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—hepatitis B	0.000139	0.000592	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-A—hepatitis B	0.000138	0.000585	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—hepatitis B	0.000135	0.000575	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—hepatitis B	0.000132	0.000562	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—hepatitis B	0.000132	0.00056	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKB1—hepatitis B	0.000131	0.000558	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—hepatitis B	0.000131	0.000554	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—hepatitis B	0.000129	0.00055	CbGpPWpGaD
Everolimus—MTOR—Disease—HLA-A—hepatitis B	0.000127	0.00054	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—hepatitis B	0.000127	0.000539	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—hepatitis B	0.000127	0.000538	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—hepatitis B	0.000126	0.000537	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—hepatitis B	0.000126	0.000536	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NFKB1—hepatitis B	0.000126	0.000535	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—hepatitis B	0.000126	0.000535	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DRB1—hepatitis B	0.000126	0.000534	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL10—hepatitis B	0.000118	0.0005	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—hepatitis B	0.000111	0.00047	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—hepatitis B	0.000105	0.000444	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—hepatitis B	9.39e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—hepatitis B	9.19e-05	0.00039	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—hepatitis B	9.14e-05	0.000388	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—hepatitis B	9.06e-05	0.000385	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—hepatitis B	8.88e-05	0.000377	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—hepatitis B	8.85e-05	0.000376	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—hepatitis B	8.83e-05	0.000375	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKB1—hepatitis B	8.79e-05	0.000373	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1B1—hepatitis B	8.56e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—hepatitis B	8.24e-05	0.00035	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GGT2—hepatitis B	8.21e-05	0.000349	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—hepatitis B	8.2e-05	0.000348	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—hepatitis B	8.17e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—hepatitis B	7.89e-05	0.000335	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—hepatitis B	7.88e-05	0.000335	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—hepatitis B	7.84e-05	0.000333	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—hepatitis B	7.7e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—hepatitis B	7.69e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKB1—hepatitis B	7.65e-05	0.000325	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—hepatitis B	7.32e-05	0.000311	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—hepatitis B	7.28e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—hepatitis B	7.11e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—hepatitis B	7.1e-05	0.000301	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—hepatitis B	6.03e-05	0.000256	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—hepatitis B	5.88e-05	0.00025	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—hepatitis B	5.52e-05	0.000234	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—hepatitis B	5.28e-05	0.000224	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—hepatitis B	5.1e-05	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—hepatitis B	4.98e-05	0.000211	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2A6—hepatitis B	4.97e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—hepatitis B	4.97e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKB1—hepatitis B	4.94e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—hepatitis B	4.8e-05	0.000204	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT2—hepatitis B	4.5e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—hepatitis B	4.43e-05	0.000188	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—hepatitis B	4.12e-05	0.000175	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GGT1—hepatitis B	3.88e-05	0.000165	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT1—hepatitis B	3.88e-05	0.000165	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—hepatitis B	3.39e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—hepatitis B	3.1e-05	0.000132	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—hepatitis B	2.07e-05	8.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—hepatitis B	1.58e-05	6.69e-05	CbGpPWpGaD
